

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Raily Aesthetic Medicine International Holdings Limited**

**瑞麗醫美國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2135)**

### **PROFIT WARNING**

This announcement is made by Raily Aesthetic Medicine International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts (the “**Unaudited Management Accounts**”) of the Group for the year ended 31 December 2024 (the “**Year 2024**”) and the information currently available to the Board, the Board expects the Group to record:

1. a revenue of approximately RMB199 million for the year ended 31 December 2024 (2023: revenue of approximately RMB189 million); and
2. a loss attributable to owners of the parent of approximately RMB59 million for the year ended 31 December 2024 (2023: loss attributable to owners of the parent of approximately RMB32 million).

The Board considers that the continued loss is mainly attributable to the following:

- (a) As disclosed in the Company’s announcement regarding provision for asset impairment dated 30 October 2024, due to business adjustments, we were no longer engaged in distribution of and ceased to be registered as a distributor for e-PTFE facial implant in the PRC. According to the results of the collective impairment tests of the Company, an impairment provision of goodwill and an impairment provision of intangible assets, offset by related deferred tax, of approximately RMB55 million, were made and contingent consideration of approximately RMB18 million was reversed, cumulatively for the year;
- (b) during the Year 2024, the share option expenses of the Group increased to approximately RMB8 million (2023: approximately RMB4 million); and

- (c) in order to accelerate the Group's research and development and production of medical equipment products, the Group increased its investment in the research and development activities of Suzhou Ruiquan Biosciences Co., Ltd.\* (蘇州瑞泉生物醫藥科技有限公司) ("**Suzhou Ruiquan**") (formerly known as "Suzhou Yonglan Biosciences Co., Ltd.\* (蘇州詠藍生物醫藥科技有限公司)"), an indirect non wholly-owned subsidiary of the Company. During the Year 2024, administrative expenses and research and development expenses of Suzhou Ruiquan amounted to approximately RMB5 million. Such expenses had not yet been recovered by the economic benefits to be derived therefrom during the Year 2024.

The information contained in this announcement is only based on the preliminary assessment by the Company's management according to the Unaudited Management Accounts and with reference to the information currently available, which have not been finalised or independently reviewed by the auditors of the Group or the audit committee of the Company, and are subject to amendments and adjustments where necessary. Shareholders of the Company and potential investors should refer to and review the annual results of the Company for the Year 2024, which are expected to be published by the end of March 2025.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Raily Aesthetic Medicine International Holdings Limited**  
**FU Haishu**  
*Chairman and Executive Director*

Hangzhou, the PRC, 10 March 2025

*As at the date of this announcement, the Board comprises Mr. Fu Haishu, Mr. Song Jianliang and Mr. Wang Ying as Executive Directors; and Mr. Cao Dequan, Ms. Yang Xiaofen and Mr. Liu Teng as Independent Non-executive Directors.*

\* For identification purposes only